Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-09-06
2008-05-06
Desai, Rita (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C546S118000
Reexamination Certificate
active
07368571
ABSTRACT:
Bicycling hydroxamate compounds represented by the Formula I:are described. The bicyclic hydroxamate compounds and compositions containing those compounds may be used to inhibit or modulate an enzyme activity of HIV Integrase and to treat HIV mediated diseases and conditions.
REFERENCES:
patent: 4371536 (1983-02-01), Braestrup et al.
patent: 5010077 (1991-04-01), Braestrup et al.
patent: 5262537 (1993-11-01), Huang et al.
patent: 5616609 (1997-04-01), Li et al.
patent: 5726203 (1998-03-01), Ikekawa et al.
patent: 6057297 (2000-05-01), Politi et al.
patent: 6075021 (2000-06-01), Evanno et al.
patent: 6395743 (2002-05-01), Heimbuch et al.
patent: 6403347 (2002-06-01), Bills et al.
patent: 7001912 (2006-02-01), Kuki et al.
patent: 7135482 (2006-11-01), Hu et al.
patent: 7138408 (2006-11-01), Kuki et al.
patent: 2002/0123527 (2002-09-01), Walker et al.
patent: 0 030 254 (1984-10-01), None
patent: 1 086 101 (2001-03-01), None
patent: 1 209 158 (2002-05-01), None
patent: 1 375 486 (2004-01-01), None
patent: 2 209 032 (1989-04-01), None
patent: 2 271 566 (1994-04-01), None
patent: 2 306 476 (1997-05-01), None
patent: 2 327 674 (1999-02-01), None
patent: 2003-119137 (2003-04-01), None
patent: 2003-171381 (2003-06-01), None
patent: WO 98/18473 (1998-05-01), None
patent: WO00/68235 (2000-11-01), None
patent: WO 01/09114 (2001-02-01), None
patent: WO 02/02516 (2002-01-01), None
patent: WO 02/070491 (2002-09-01), None
patent: WO 03/033496 (2003-04-01), None
patent: WO 03/035076 (2003-05-01), None
patent: WO 03/047564 (2003-06-01), None
patent: WO 03/049690 (2003-06-01), None
patent: WO 03/062204 (2003-07-01), None
patent: WO 03/077850 (2003-09-01), None
patent: WO 03/082881 (2003-10-01), None
patent: WO 03/086319 (2003-10-01), None
patent: WO 2004/035076 (2004-04-01), None
patent: WO 2004/039803 (2004-05-01), None
patent: WO 2004/067531 (2004-08-01), None
patent: WO 2005/103003 (2005-11-01), None
patent: WO 2005/103051 (2005-11-01), None
patent: WO 2006/027694 (2006-03-01), None
Abdel-Magid, A., et al., “Reductive Amination of Aldehydes and Ketones by Using Sodium Triacetoxyborohydride,”Tetrahedron Letters, 1990, 5595-5598, vol. 31, No. 39.
Abdel-Magid, et al., “Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures,”Journal of Organic Chemistry, 1996, 3849-3862, vol. 61.
Amatore, C., et al., “Intimate Mechanism Of Oxidative Addition To Zerovalent Palladium Complexes In The Presence Of Halide Ions And Its Relevance To The Mechanism Of Palladium-Catalyzed Nucleophilic Substitutions,”J. Am. Chem. Soc., 1993, 9531-9541, vol. 115.
Bagshawe, K., “Antibody-Directed Enzyme Prodrug Therapy: A Review,”Drug Development Research, 1995, 220-230, vol. 34.
Barbier, C., et al., “Preparation of Lavendamycin Analogues,”Heterocycles, 2000, 37-48, vol. 53, No. 1.
Bertolini, et al., “A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immonsuppresive Drug,”Journal of Medicinal Chemistry, 1997, 2011-2016, vol. 40.
Biere, H., et al., “Ein einfacher Zugang zum Pyrrolo[1,2-c]pyrimidin und Pyrrolo[3,2-c]pyridin-System,”Liebigs Ann. Chem., 1987, 491-497 (English Abstract Enclosed).
Bodor, “Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems,”Advances in Drug Research, 1984, 255-331, vol. 13.
Butler, S., et al., “A Quantitative Assay for HIV DNA Integration in vivo,”Nature Medicine, 2001, 631-634, vol. 7, No. 5.
Cain, M., et al., “Biomimetic Approach to Potential Benzodiazepine Agonists and Antagonists,”Heterocycles, 1982, 1003-1007, vol. 19, No. 6.
Campbell, K., et al., “The Preparation of unsymmetrical Secondary Aliphatic Amines,”J. Am. Chem. Soc., 1944, 82-84, vol. 66.
Chen, B., et al., “Distinct Modes Of Human Immunodeficiency Virus Type 1 Proviral Latency Revealed By Superinfection Of Nonproductively Infected Cell Lines With Recombianant Luciferase-Encoding Viruses”Journal Of Virology, 1994, 654-660, vol. 68, No. 2.
Chen, J., et al., “Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: A model for viral DNA binding,”PNAS, 2000, 8233-8238, vol. 97, No. 15.
Coker, J., et al., “The Cyanomethylation of Indole,”Journal of Organic Chemistry, 1963, 589-590, vol. 28.
Dear, G., et al., “Mass directed peak selection, an efficient method of drug metabolite identification using directly coupled liquid chromatography—mass spectrometry—nuclear magnetic resonance spectroscopy,”Journal of Chromatography B, 2000, 281-293, vol. 748.
Dekhane, M., et al., “A New Efficient Synthesis of Ethyl β-Carboline-3-Carboxylate (β-CCE) and Methyl 4-Methyl-β-Carboline-3-Carboxylate (4-Methyl-β-CCM) Starting from Indole-2-Carboxaldehyde,”Tetrahedron, 1994, 6299-6306, vol. 50, No. 21.
Dekhane, M., et al., “A Practical Synthesis of 1h-Pyrrlo[2,3-c]Pyridine-5-Carboxylic Acid Derivatives From Pyrrole-2-Carboxaldehydes,”Tetrahedron, 1993, 8139-8146, vol. 49, No. 36.
Dodd, R., et al., “Synthesis and Pharmacological Activity of a Pyrido [3′,4′:5,4]Pyrrolo[1,2-c]-[1,4] Benzodiazepine-3, 10-Dione, A New Benzodiazepine-β--Carboline Type Hybrid Molecule,”Heterocycles, 1989, 1101-1113, vol. 28, No. 2.
Dodd, R., et al., “The Oxidation of Aromatic Aldehydes to Carboxylic Acids Using Hydrogen Peroxide in Formic Acid,”Synthesis, 1993, 295-297.
Doisy, X., et al., “Synthesis And Benzodiazephine Receptor (ω Receptor) Affinities Of 3-Substituted Derivatives Of Pyrrolo[2,3-c]Pyridine-5-Carboxylate, A Novel Class of ω1Selective Ligands,”Bioorganic&Medicinal Chemistry, 1999, 921-932, vol. 7.
Doyle, T., et al., “Nuclear Analogs of β-lactam Antibiotics. I. Synthesis of O-2-isocephams,”Can. J. Chem., 1977, 468-483, vol. 55.
Eberle, M., “Contribution to the Chemistry of Indole About the 5-(1-Indolyl)-2-pentanone System,”Journal of Organic Chemistry, 1976, 633-636, vol. 41, No. 4.
Erofeev, Y., et al., “Introduction of 3-Indolymethyl Residues in Nitroacetic Acid Esters,”Khim. Get. Soed., 1978, 780.
Gilchrist, T., et al., “Synthesis of Fused Pyridines under Neutral Conditions,”J.C.S. Chem. Comm., 1979, 627-628.
Goldgur, Y., et al., “Structure Of the HIV-1 Integrase Catalytic Domain Complexed With An Inhibitor: A Platform For Antiviral Drug Design,”PNAS, 1999, 13040-13043, vol. 96, No. 23.
Grobler, J., et al., “Diketo Acid Inhibitor Mechanism And HIV-1 Integrase: Implications For Metal Binding In The Active Site Of Phosphotransferase Enzymes,”PNAS, 2002, 6661-6666, vol. 99, No. 10.
Guzman, F., et al., “Biomimetic Approach to Potential Benzodiazepine Receptor Agonists and Antagonists,”Journal of Medicinal Chemistry, 1984, 564-570, vol. 27.
Hansen, M., et al., “Integration Complexes Derived From HIV Vectors For Rapid Assays In Vitro,”Nature Biotechnology, 1999, 578-582, vol. 17, No. 6.
Hazuda, D., et al., “Discovery and Analysis of Inhibitors of the Human Immunodeficiency Integrase,”Drug Design and Discovery, 1997, 17-24, vol. 15.
Henn, L., et al., “Formation of Indoles, Isoquinolines, and Other Fused Pyridines from Azidocrylates,”J. Chem. Soc. Perkin Trans., 1984, 2189-2196, vol. 1.
Ho, B., et al. “Inhibitors of Monoamine Oxidase: Influence of Methyl Substitution on the Inhibitory Activiy of beta-Carbolines,”J. Pharm.Sci., 1968, 269-274, vol. 57, No. 2.
Ho, B., et al., “Inhibitors of Monoamine Oxidase III: 9-Substituted beta-Carbolines,”J.Pharm Sci., 1969, 219-221, vol. 58, No. 2.
Hughes, L., et al., “Progress In The Mitsunobu Reaction, A Review,”Organic Preparations And Procedures Int., 1996, 127-164, vol. 28, No. 2.
Jenkins, T., et
Hu Qiyue
Kuki Atsuo
Nowlin Dawn Marie
Plewe Michael Bruno
Wang Hai
Desai Rita
Kershner David L.
Mabry John
Pfizer Inc
Zelson Steve T.
LandOfFree
HIV-Integrase inhibitors, pharmaceutical compositions and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HIV-Integrase inhibitors, pharmaceutical compositions and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV-Integrase inhibitors, pharmaceutical compositions and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3985562